Artwork

Contenuto fornito da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.
Player FM - App Podcast
Vai offline con l'app Player FM !

Episode 36. ASH 2023 Lymphoma Recap with Dr. Toby Eyre

50:59
 
Condividi
 

Manage episode 390589137 series 3369804
Contenuto fornito da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.

Here are the abstracts that were discussed:

Mantle Cell Lymphoma

1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180069.html

2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)

https://ash.confex.com/ash/2023/webprogram/Paper191921.html

Chronic Lymphocytic Leukemia

1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063

2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:

https://ash.confex.com/ash/2023/webprogram/Paper187128.html

Hodgkin Lymphoma

1. S1826 outcomes in older adults:

https://ash.confex.com/ash/2023/webprogram/Paper180114.html

Diffuse Large B-cell Lymphoma

1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180381.html

2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper177588.html

  continue reading

57 episodi

Artwork
iconCondividi
 
Manage episode 390589137 series 3369804
Contenuto fornito da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff. Tutti i contenuti dei podcast, inclusi episodi, grafica e descrizioni dei podcast, vengono caricati e forniti direttamente da Rajshekhar Chakraborty and Ashwin Kishtagari, Rajshekhar Chakraborty, Ashwin Kishtagari, and Edward Cliff o dal partner della piattaforma podcast. Se ritieni che qualcuno stia utilizzando la tua opera protetta da copyright senza la tua autorizzazione, puoi seguire la procedura descritta qui https://it.player.fm/legal.

In this episode, we review the hottest updates in lymphoma from the American Society of Hematology 2023 meeting with Dr Toby Eyre, a consultant haematologist at the University of Oxford in the UK.

Here are the abstracts that were discussed:

Mantle Cell Lymphoma

1. BOVen trial-A Multicenter Phase 2 Trial of Zanubrutinib, Obinutuzumab, and Venetoclax in Patients with Treatment-Naïve, TP53-Mutant Mantle Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180069.html

2. SYMPATICO Trial: Ibrutinib Combined with Venetoclax in Patients with Relapsed/Refractory Mantle Cell Lymphoma (Late Breaking Abstract)

https://ash.confex.com/ash/2023/webprogram/Paper191921.html

Chronic Lymphocytic Leukemia

1. FLAIR trial: Chronic Lymphocytic Leukemia Therapy Guided by Measurable Residual Disease

Link for simultaneous NEJM publication: https://www.nejm.org/doi/10.1056/NEJMoa2310063

2. Ibrutinib retreatment in Phase 2 CAPTIVATE study:

https://ash.confex.com/ash/2023/webprogram/Paper187128.html

Hodgkin Lymphoma

1. S1826 outcomes in older adults:

https://ash.confex.com/ash/2023/webprogram/Paper180114.html

Diffuse Large B-cell Lymphoma

1. Smart STOP study: Lenalidomide, Tafasitamab, Rituximab, and Acalabrutinib Alone and with Combination Chemotherapy for the Treatment of Newly Diagnosed Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper180381.html

2. Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma

https://ash.confex.com/ash/2023/webprogram/Paper177588.html

  continue reading

57 episodi

Tutti gli episodi

×
 
Loading …

Benvenuto su Player FM!

Player FM ricerca sul web podcast di alta qualità che tu possa goderti adesso. È la migliore app di podcast e funziona su Android, iPhone e web. Registrati per sincronizzare le iscrizioni su tutti i tuoi dispositivi.

 

Guida rapida

Ascolta questo spettacolo mentre esplori
Riproduci